Lennox Gastaut Syndrome Market Expected to rise, 2034 | GlaxoSmithKline, Meda Pharmaceuticals, Roche, Lundbeck, Greenwich Biosciences, Janssen Pharmaceuticals, Eisai, Zogenix, Takeda, Ovid Therapeutic

The Lennox Gastaut Syndrome market growth is driven by factors like increase in the prevalence of Lennox Gastaut Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Lennox Gastaut Syndrome market report [https://www.delveinsight.com/report-store/lennox-gastaut-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Lennox Gastaut Syndrome market size, share, Lennox Gastaut Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Lennox Gastaut Syndrome market size growth forward.

Some of the key highlights from the Lennox Gastaut Syndrome Market Insights Report:

*
Several key pharmaceutical companies, including GlaxoSmithKline, Meda Pharmaceuticals, Roche, Lundbeck, Greenwich Biosciences, Janssen Pharmaceuticals, Eisai, Zogenix, Takeda, Ovid Therapeutics, and others, are developing novel products to improve the Lennox Gastaut Syndrome treatment outlook.

*
In September 2024, a European real-world study presented at the 15th European Epilepsy Congress emphasized the need for faster and more accurate diagnoses of Lennox-Gastaut Syndrome (LGS). The study, which used data from the Adelphi LGS Disease Specific Programme Trademark (DSP), involved 454 pediatric and adult LGS patients across Europe. The findings revealed that, on average, it takes 12.3 months to receive an accurate LGS diagnosis after the first seizure, which typically occurs at around 4 years of age. This highlights the prolonged delay that patients and their families experience in obtaining a correct diagnosis in Europe.

*
In June 2024, Takeda announced Phase 3 Topline Results for Soticlestat (TAK-935) in Patients suffering with Lennox-Gastaut Syndrome

*
In 2023, DelveInsight estimated that there were approximately 81,000 diagnosed prevalent cases of Lennox Gastaut Syndrome (LGS) across the 7MM. The United States represented 42.6% of these cases, while the EU4 and the UK accounted for around 53.7%, and Japan contributed about 3.8%.

*
The LGS market is poised for steady growth, with a strong compound annual growth rate (CAGR) expected from 2024 to 2034. This growth across the 7MM will be driven by the launch of new therapies, including EPX-100 and Carisbamate, among others. Increased awareness of LGS is also leading to earlier diagnoses and improved management, which, in turn, is boosting the demand for effective treatments and expanding the market. DelveInsight's analysis predicts the LGS market will grow at a CAGR of 4.5% from 2024 to 2034.

*
Several newly approved therapies targeting seizure control in LGS, such as EPIDIOLEX (cannabidiol) and FINTEPLA (fenfluramine), offer more treatment options, addressing the unmet needs of patients resistant to traditional antiepileptic drugs, which will further contribute to market growth. Despite these advances, LGS treatment faces challenges like poor seizure control and drug resistance in many patients. Existing therapies often struggle to manage all seizure types, and side effects like cognitive decline and sedation limit their effectiveness. Moreover, the lack of long-term safety data highlights the need for more targeted and tolerable treatments.

*
As per DelveInsight analysis, the Lennox Gastaut Syndrome market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Lennox Gastaut Syndrome Market Landscape [https://www.delveinsight.com/sample-request/lennox-gastaut-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Lennox Gastaut Syndrome Overview

Lennox Gastaut Syndrome (LGS) is a severe form of pediatric epilepsy marked by multiple drug-resistant seizure types, such as tonic seizures, atypical absences, and tonic or atonic drop attacks, along with electroencephalographic abnormalities like slow-spike waves and paroxysmal fast rhythms. Common comorbidities include intellectual disability, as well as behavioral and psychiatric disorders, all of which have a multifactorial origin.

In addition to the typical seizures, LGS patients may experience other seizure types, including myoclonic seizures, focal seizures, and non-convulsive status epilepticus, particularly in the later stages of the disorder. While intellectual disability is common in most patients, it is not always present, so it should not be used as a definitive diagnostic criterion.

The diagnosis of LGS is generally made through a comprehensive clinical assessment, including a detailed patient history and physical and neurological evaluations, supplemented by advanced imaging techniques such as electroencephalography (EEG) and magnetic resonance imaging (MRI).

LGS can be distinguished from other epilepsy syndromes through patient history and EEG findings, but achieving a precise diagnosis can be challenging. Not all patients with LGS exhibit the classic triad of symptoms, especially at the disease's onset. Despite well-established diagnostic criteria, there is considerable overlap between LGS and other early-onset epileptic encephalopathies. For example, drop attacks, commonly observed in LGS, are also present in other syndromes. Epilepsies with similar features to LGS include focal epilepsies with secondary bilateral synchrony, myoclonic-astatic epilepsy (Doose syndrome), Dravet syndrome, West syndrome, and atypical benign partial epilepsy of childhood.

Do you know the treatment paradigms for different countries? Download our Lennox Gastaut Syndrome Market Sample Report [https://www.delveinsight.com/sample-request/lennox-gastaut-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Lennox Gastaut Syndrome Epidemiology Insights

*
As per DelveInsight, in 2023, the United States had the highest number of diagnosed prevalent cases of Lennox Gastaut Syndrome, with approximately 34,000 cases, and this number is expected to rise during the forecast period.

*
Within the US, the diagnosed prevalent cases of LGS were distributed by gender, with males representing about 25,000 cases and females making up around 9,000 cases.

Lennox Gastaut Syndrome Epidemiology Segmentation

DelveInsight's Lennox Gastaut Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Lennox Gastaut Syndrome historical patient pools and forecasted Lennox Gastaut Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Lennox Gastaut Syndrome Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Lennox Gastaut Syndrome Prevalence

*
Age-Specific Lennox Gastaut Syndrome Prevalence

*
Gender-Specific Lennox Gastaut Syndrome Prevalence

*
Diagnosed and Treatable Cases of Lennox Gastaut Syndrome

Visit for more @ Lennox Gastaut Syndrome Epidemiological Insights [https://www.delveinsight.com/report-store/lennox-gastaut-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Lennox Gastaut Syndrome Market Outlook

The Lennox Gastaut Syndrome market is evolving with a focus on addressing significant gaps in treatment efficacy and safety. Currently, the market is primarily driven by established antiepileptic drugs (AEDs) such as valproate, lamotrigine, and topiramate, which are foundational treatments but often insufficient for refractory cases. The introduction of cannabinoids, particularly EPIDIOLEX (cannabidiol), has provided a notable alternative, targeting severe, drug-resistant seizures through a unique mechanism of action.

The development pipeline shows strong promise, with numerous new drug candidates and treatment approaches in the works. The market is also gaining momentum due to the urgent need for more effective therapies, especially given the limited options available for patients with refractory Lennox Gastaut Syndrome.

Regulatory designations such as Orphan Drug and Rare Pediatric Disease status are boosting the market potential for emerging therapies, driving both investment and innovation. Overall, the Lennox Gastaut Syndrome market is characterized by a high demand for novel treatments that can offer improved seizure control and enhance the quality of life for patients.

Lennox Gastaut Syndrome Marketed Drugs

*
FINTEPLA (fenfluramine): UCB

*
EPIDIOLEX (cannabidiol): Jazz Pharmaceuticals

Lennox Gastaut Syndrome Emerging Drugs

*
EPX-100: Epygenix

*
Carisbamate: SK Life Science

Lennox Gastaut Syndrome Key Companies

*
GlaxoSmithKline, Meda Pharmaceuticals, Roche, Lundbeck, Greenwich Biosciences, Janssen Pharmaceuticals, Eisai, Zogenix, Takeda, Ovid Therapeutics, and others

For more information, visit Lennox Gastaut Syndrome Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/lennox-gastaut-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Lennox Gastaut Syndrome Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Lennox Gastaut Syndrome, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Lennox Gastaut Syndrome epidemiology in the 7MM

*
Lennox Gastaut Syndrome marketed and emerging therapies

*
Lennox Gastaut Syndrome companies

*
Lennox Gastaut Syndrome market drivers and barriers

Table of Contents:

1 Lennox Gastaut Syndrome Market Key Comprehensive Insights

2 Lennox Gastaut Syndrome Market Report Introduction

3 Competitive Intelligence Analysis for Lennox Gastaut Syndrome

4 Lennox Gastaut Syndrome Market Analysis Overview at a Glance

5 Executive Summary of Lennox Gastaut Syndrome

6 Lennox Gastaut Syndrome Epidemiology and Market Methodology

7 Lennox Gastaut Syndrome Epidemiology and Patient Population

8 Lennox Gastaut Syndrome Patient Journey

9 Lennox Gastaut Syndrome Treatment Algorithm, Lennox Gastaut Syndrome Current Treatment, and Medical Practices

10 Key Endpoints in Lennox Gastaut Syndrome Clinical Trials

11 Lennox Gastaut Syndrome Marketed Therapies

12 Lennox Gastaut Syndrome Emerging Therapies

13 Lennox Gastaut Syndrome: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Lennox Gastaut Syndrome

16 Lennox Gastaut Syndrome Market Key Opinion Leaders Reviews

18 Lennox Gastaut Syndrome Market Drivers

19 Lennox Gastaut Syndrome Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Lennox Gastaut Syndrome Epidemiology 2034

DelveInsight's "Lennox Gastaut Syndrome - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Lennox Gastaut Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Lennox Gastaut Syndrome Pipeline 2024

"Lennox Gastaut Syndrome Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Lennox Gastaut Syndrome market. A detailed picture of the Lennox Gastaut Syndrome pipeline landscape is provided, which includes the disease overview and Lennox Gastaut Syndrome treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lennox-gastaut-syndrome-market-expected-to-rise-2034-glaxosmithkline-meda-pharmaceuticals-roche-lundbeck-greenwich-biosciences-janssen-pharmaceuticals-eisai-zogenix-takeda-ovid-therapeutic]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.